Novartis Pharmaceuticals Corp.’s Phase III study of Afinitor (everolimus) tablets plus best supportive care met its primary endpoint in patients with advanced pancreatic neuroendocrine tumors (NET). Results showed that the drug significantly extended progression-free survival, or time without tumor growth. Currently, surgery and chemotherapy are the only approved treatment options for patients with advanced pancreatic NET. Everolimus is approved under the trade name Afinitor (everolimus) tabl...